|
|
Simcere Buys 35% Stake of Antibody Company, Announces Q1 Results
publication date: May 19, 2009
Simcere Pharmaceutical Group (先声药业) disappointed investors with its Q1 financial report. The company announced revenues of $64.8 million, a 12% increase from the year earlier, but $5 million less than the average analyst forecast. Net income was $7.1 million, a 57% decrease from 2008. At the same time, Simcere said it will acquire 35% of Shanghai Celgen Bio-Pharmaceutical Co., Ltd. for 140 million RMB ($20.6 million), a company that focuses on research and production of therapeutic antibodies. More details... Stock Symbol: (NYSE: SCR)
|
ChinaBio® Events
ChinaBio® Partnering Forum 2012May 23-24, 2012 Suzhou, China >>More events...
Partner Events
 China Healthcare Investment Conference 2012March 13-15, 2012 Shanghai, China Shanghai CEO ConferenceMarch 28-29, 2012 Shanghai, China >>More details...
Other Events
China Pharmaceutical R&D SummitApril 23-26, 2012 Shanghai, China Biosimilars Asia 2012April 23-26, 2012 Shanghai, China Vaccines China 2012April 23-26, 2012 Shanghai, China
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners
![]()
|